Private DNA synthesis firm Twist Biotech has bought Genome Compiler, an Israel-based company which provides software for genetic engineers, molecular and synthetic biologists.
USA-based Twist has a DNA manufacturing process featuring a silicon platform which allows it to produce synthetic biology tools on a vast scale including synthetic biology tools, oligonucleotide pools and variant libraries.
Its DNA is already used by many of the world’s big pharma companies along with other members of the synthetic and molecular biology communities to further their research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze